WO2012074126A1 - Bicyclic compound - Google Patents

Bicyclic compound Download PDF

Info

Publication number
WO2012074126A1
WO2012074126A1 PCT/JP2011/078010 JP2011078010W WO2012074126A1 WO 2012074126 A1 WO2012074126 A1 WO 2012074126A1 JP 2011078010 W JP2011078010 W JP 2011078010W WO 2012074126 A1 WO2012074126 A1 WO 2012074126A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
compound
optionally substituted
ring
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2011/078010
Other languages
English (en)
French (fr)
Other versions
WO2012074126A9 (en
Inventor
Tsuneo Yasuma
Makoto Kamata
Tohru Yamashita
Hideki Hirose
Masataka Murakami
Asato Kina
Kazuko Yonemori
Ryo Mizojiri
Ikuo Fujimori
Takuya Fujimoto
Zenichi Ikeda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020137016850A priority Critical patent/KR20140001965A/ko
Priority to ES11802168.2T priority patent/ES2536319T3/es
Priority to BR112013013417A priority patent/BR112013013417A2/pt
Priority to JP2013524677A priority patent/JP5824517B2/ja
Priority to AU2011337565A priority patent/AU2011337565A1/en
Priority to CN201180066388.XA priority patent/CN103347872B/zh
Priority to PH1/2013/501099A priority patent/PH12013501099A1/en
Priority to EP11802168.2A priority patent/EP2649062B1/en
Priority to EA201390794A priority patent/EA201390794A1/ru
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Priority to SG2013041546A priority patent/SG190925A1/en
Priority to CA2819400A priority patent/CA2819400A1/en
Priority to MX2013006113A priority patent/MX2013006113A/es
Publication of WO2012074126A1 publication Critical patent/WO2012074126A1/en
Priority to TNP2013000230A priority patent/TN2013000230A1/fr
Anticipated expiration legal-status Critical
Priority to MA35965A priority patent/MA34713B1/fr
Publication of WO2012074126A9 publication Critical patent/WO2012074126A9/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to a bicyclic compound having an acetyl-CoA carboxylase (in the present specification, sometimes to be abbreviated as ACC) inhibitory action, which is useful for the prophylaxis or treatment of obesity,
  • ACC acetyl-CoA carboxylase
  • diabetes hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like.
  • ACC is an enzyme, that converts acetyl-CoA to malonyl-CoA, and catalyzes a rate determining reaction in fatty acid
  • ACC plays a key role in controlling the balance between use of carbohydrate and fatty acid in the liver and skeletal muscle, and further, controlling insulin sensitivity in the liver, skeletal muscle and adipose tissue.
  • a reduced level of malonyl-CoA by ACC inhibition can promote a promotion in fatty acid oxidation, decreased
  • TG triglyceride
  • VLDL triglyceride-rich lipoprotein
  • long-term administration of a compound having an ACC inhibitory action can strikingly decrease the TG content of the liver and adipose tissues and selectively
  • a compound having an ACC inhibitory action is extremely useful for the prophylaxis or treatment of metabolic syndrome, obesity, hypertension, diabetes,
  • cardiovascular diseases associated with atherosclerosis and the like.
  • patent document 1 (WO 2010/050445) has reported the following compound.
  • A is an acyl group or an optionally substituted 5- or 6- membered aromatic ring group
  • ring M is an optionally condensed 5- to 7-membered ring which is . optionally further substituted;
  • ring P is an optionally further substituted 5-membered heterocycle
  • ring Q is an optionally further substituted 6- membered ring
  • ring P and ring Q are fused to form an optionally further substituted bicyclic aromatic heterocycle
  • ring P is an optionally further substituted 5-membered non-aromatic ring
  • ring Q is an optionally further substituted 6-membered aromatic ring
  • ring P and ring Q are fused to form an optionally further substituted bicyclic non-aromatic ring
  • R 1 is an optionally substituted Ci_ 6 alkyl group or an optionally substituted C 3 _ 6 cycloalkyl group
  • R A1 is a hydrogen atom or a Ci_ 6 alkyl group
  • R A2 , R A3 , R A4 , R A5 and R A7 are independently a hydrogen atom or a Ci_6 alkyl group; and R A6 is a hydrogen atom, a Ci-6 alkyl group or a hydroxy group,
  • non-patent document 1 (Analytical Sciences
  • patent document 2 (WO 2011/136385) has reported the following compound.
  • R 1 is a group represented by the formula: -COR 2 wherein R 2 is a hydrogen atom or a substituent, an optionally substituted 5- or 6-membered aromatic heterocyclic group or an optionally substituted phenyl group;
  • R 3 is a Ci-6 alkyl group optionally substituted by halogen atom(s), or an optionally substituted C 3 - 6 cycloalkyl group;
  • R 4 is a hydrogen atom or a substituent;
  • X is 0, CO , CR 5a R 5b wherein R 5a and R 5b are each independently a hydrogen atom, a halogen atom or an optionally substituted Ci_ 6 alkyl group, NR 5c wherein R 5c is a hydrogen atom or an
  • Ci-6 alkyl group optionally substituted Ci-6 alkyl group, S , SO or S(0) 2 ;
  • ring A is an optionally further substituted 4- to 7-membered non-aromatic ring (the ring is optionally crosslinked) ;
  • ring P is a 5-membered aromatic heterocycle
  • ring Q is an optionally further substituted 6-membered ring
  • ring P and ring Q are condensed to form an optionally further substituted bicyclic aromatic heterocycle
  • R 6 is an optionally substituted Ci- 6 alkyl group or an
  • R 1 is a group represented by the formula: -COR 2 wherein R 2 is a hydrogen atom or a substituent, or an optionally substituted 5- or 6-membered aromatic ring group;
  • R 3 is a C-6 alkyl group optionally substituted by halogen atom(s), or an optionally substituted C 3 _ 6 cycloalkyl group;
  • R a and R b are independently a hydrogen atom or a substituent;
  • X is 0, CO, CR 5a R 5b wherein R 5a and R 5b are independently a hydrogen atom or a substituent, NR 5c wherein R 5c is a hydrogen atom or an optionally substituted Ci_ 6 alkyl group, S, SO, or S(0) 2 ;
  • ring A is an optionally further substituted 5- or 6-membered aromatic ring
  • ring P is an optionally further substituted 5-membered aromatic ring
  • ring Q is an optionally further substituted 6- membered ring
  • ring P and ring Q are fused to form an optionally further substituted bicyclic aromatic ring, or
  • ring P is an optionally further substituted 5-membered non-aromatic ring
  • ring Q is an optionally further substituted 6-membered aromatic ring
  • ring P and ring Q are fused to form an optionally further substituted bicyclic non-aromatic ring
  • R 6 is an optionally substituted Ci_ 6 alkyl group or an
  • compound (I) has a superior ACC inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic
  • the present invention relates to
  • Ci_6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • R 3 is a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • R a and R b are each a hydrogen atom
  • X is 0, CO or CH 2 ,
  • R 6 is a Ci-6 alkyl group optionally substituted by 1 to 3 substituents selected from
  • ring A is benzene, optionally oxidized pyridine, pyrimidine, pyrazole or isoxazole, each of which is optionally substituted by 1 to 3 substituents selected from
  • Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • [11A] a prodrug of the compound or salt of the above-mentioned [1], [2], [3], [4], [5], [6], [7], [8], [9], [10] or [11];
  • [15] a method of inhibiting acetyl-CoA carboxylase in a mammal, which comprises administering an effective amount of the compound or salt of the above-mentioned [1], [2], [3], [4],
  • Compound (I) has an ACC inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic
  • halogen atom in the present specification means, unless otherwise specified, a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
  • Ci-6. alkyl group in the present specification means, unless otherwise specified, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1 , 1-dimethylbutyl, 2, 2-dimethylbutyl, 3, 3-dimethylbutyl, 2-ethylbutyl or the like.
  • Ci_6 alkoxy group in the present specification means, unless otherwise specified, methoxy, ethoxy, propoxy,
  • R 1 is a group represented by the formula: -COR 2 wherein R 2 is a hydrogen atom or a substituent, or an optionally
  • hydrocarbon group examples include a Ci-io alkyl group, a C 2 -io alkenyl group, a C 2 -io alkynyl group, a C3-10 cycloalkyl group, a C 3 _io cycloalkenyl group, a C4-10
  • Ci-10 alkyl group examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1, 1-dimethylbutyl, 2, 2-dimethylbutyl, 3, 3-dimethylbutyl, 2- ethylbutyl, heptyl, octyl, nonyl, decyl and the like. Of these, a Ci-6 alkyl group is preferable.
  • Examples of the C 2 -io alkenyl group include ethenyl, 1- propenyl, 2-propenyl, 2-methyl-l-propenyl, 1-butenyl, 2- butenyl, 3-butenyl, 3-methyl-2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 3- hexenyl, 5-hexenyl, 1-heptenyl, 1-octenyl and the like. Of these, a C 2 -6 alkenyl group is preferable.
  • Examples of the C 2 -i 0 alkynyl group include ethynyl, 1- propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1- pentynyl, 2-pentynyl, 3-pentynyl,- 4-pentynyl, 1-hexynyl, 2- hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-heptynyl, 1- octynyl and the like.
  • a C 2 -6 alkynyl group is
  • Examples of .the C3-10 cycloalkyl group include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like. Of these, a C3-6 cycloalkyl group is preferable.
  • Examples of the C3-10 cycloalkenyl group include 2- cyclopenten-l-yl, 3-cyclopenten-l-yl, 2-cyclohexen-l-yl, 3- cyclohexen-l-yl and the like. Of these, a C3_6 cycloalkenyl group is preferable.
  • Examples of the G4-10 cycloalkadienyl group include 2,4- cyclopentadien-l-yl, 2, -cyclohexadien-l-yl, 2,5- cyclohexadien-l-yl and the like. Of these, a C- 6
  • cycloalkadienyl group is preferable.
  • cycloalkenyl group and C4-10 cycloalkadienyl group are each optionally fused with a benzene ring to form a fused ring group.
  • fused ring group examples include indanyl, dihydronaphthyl, tetrahydronaphthyl, fluorenyl and the like.
  • C3-10 cycloalkyl group, C3-10 ' cycloalkenyl group and C4-10 cycloalkadienyl group may be - each a C 7 _i 0 bridged hydrocarbon group.
  • Examples of the C 7 _io . bridged hydrocarbon group include bicyclo [2.2.1] heptyl
  • cycloalkane a C3-10 cycloalkene or a C4-10 cycloalkadiene.
  • Examples of the C3-10 cycloalkane, C3-10 cycloalkene and C -10 cycloalkadiene include rings corresponding to the above- mentioned C3-10 cycloalkyl group, C3-10 cycloalkenyl group and C 4 _ 10 cycloalkadienyl group.
  • Examples of the spiro ring group include spiro [4.5] decan-8-yl and the like.
  • Examples of the C 6 -i 4 aryl group include phenyl, naphthyl, anthryl, phenanthryl, acenaphthylenyl, biphenylyl and the like. Of these, a C 6 -i2 aryl group is preferable.
  • Examples of the C 7 -i 3 aralkyl group include benzyl,
  • Examples of the Cg-i3 arylalkenyl group include styryl and the like.
  • Ci-io alkyl group, C 2 -io alkenyl group and C 2 -io alkynyl group which are exemplified as the above-mentioned
  • hydrocarbon . group optionally, have 1 to 7 (preferably 1 to 3) substituents at substitutable positions.
  • a C3-10 cycloalkyl group e.g., cyclopropyl, cyclohexyl
  • a C3-10 cycloalkyl group e.g., cyclopropyl, cyclohexyl
  • Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • Ci-6 alkoxy group optionally substituted by 1 to 3 halogen atoms
  • an aromatic heterocyclic group e.g., thienyl, furyl, pyridyl, pyrazolyl, imidazolyl, tetrazolyl, oxazolyl,
  • Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • Ci-6 alkoxy group optionally substituted by 1 to 3 halogen atoms
  • a halogen atom (d) a halogen atom; (4) a non-aromatic heterocyclic group (e.g., tetrahydrofuryl, morpholinyl, thiomorpholinyl, piperidyl, pyrrolidinyl,
  • a non-aromatic heterocyclic group e.g., tetrahydrofuryl, morpholinyl, thiomorpholinyl, piperidyl, pyrrolidinyl,
  • piperazinyl optionally substituted by 1 to 3 substituents selected from
  • Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • Ci-6 alkoxy group optionally substituted by 1 to 3 halogen atoms
  • Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • Ci-6 alkyl-carbonyl group optionally substituted by 1 to 3 halogen atoms
  • Ci-6 alkoxy-carbonyl group optionally substituted by 1 to 3 halogen atoms
  • Ci_6 alkylsulfonyl group e.g., methylsulfonyl
  • halogen atoms e.g., methylsulfonyl
  • an aromatic heterocyclic group e.g., thienyl, furyl, pyridyl, pyrazolyl, imidazolyl, tetrazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl
  • an aromatic heterocyclic group e.g., thienyl, furyl, pyridyl, pyrazolyl, imidazolyl, tetrazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl
  • Ci-6 alkyl-carbonyl group optionally substituted by 1 to 3 halogen atoms
  • Ci-6 alkoxy-carbonyl group optionally substituted by 1 to 3 substituents selected from
  • a C6-1 aryl group e.g., phenyl
  • a heterocyclic group e.g., tetrahydrofuryl
  • a Ci-6 alkylsulfonyl group e.g., methylsulfonyl
  • Ci-6 alkoxy group optionally substituted by 1 to 3 substituents selected from
  • Ci-6 alkoxy-carbonyl group optionally substituted by 1 to 3 C6-14 aryl groups (e.g., phenyl),
  • a C 2 -6 alkenyloxy group e.g., ethenyloxy
  • a C 2 -6 alkenyloxy group e.g., ethenyloxy
  • 1 to 3 halogen atoms optionally substituted by 1 to 3 halogen atoms
  • a C 7 -i3 aralkyloxy group e.g., benzyloxy
  • a C 6 -i4 aryloxy group e.g., phenyloxy,' naphthyloxy
  • Ci-6 alkyl-carbonyloxy group e.g., acetyloxy, tert- butylcarbonyloxy
  • Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • a non-aromatic heterocyclylcarbonyl group e.g.,
  • Ci_6 alkyl groups optionally substituted by 1 to 3 halogen atoms;
  • Ci-6 alkylthio group e.g., methylthio, ethylthio
  • substituents selected from
  • a C 6 -i4 arylthio group e.g., phenylthio, naphthylthio
  • Ci-3 alkyleneoxy group e.g., methyleneoxy, ethyleneoxy
  • an aromatic heterocyclylcarbonyl group e.g., an aromatic heterocyclylcarbonyl group
  • pyrazolylcarbonyl pyrazinylcarbonyl, isoxazolylcarbonyl, pyridylcarbonyl, thiazolylcarbonyl) optionally substituted by 1 to 3 substituents selected from a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms;
  • a C 3 _io cycloalkoxy group e.g., cyclopropoxy
  • halogen atom e.g., a fluorine atom
  • Ci-6 alkoxy group e.g., methoxy
  • Ci_6 alkoxy-carbonyl group a Ci_6 alkoxy-carbonyl group
  • Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms
  • heterocyclic group of the above- mentioned “optionally substituted heterocyclic group” include an “aromatic heterocyclic group” and a “non-aromatic
  • aromatic heterocyclic group examples include a 4- to 7-membered (preferably 5- or 6-menbered) monocyclic aromatic heterocyclic group containing, as a ring-constituting atom besides carbon atoms, 1 to 4 hetero atoms selected from an oxygen atom, a sulfur atom and a nitrogen atom, and a fused aromatic heterocyclic group.
  • fused aromatic heterocyclic group examples include a group derived from a fused ring wherein a ring corresponding to the 4- to 7-membered
  • nitrogen atoms e.g., pyrrole, imidazole, pyrazole, pyrazine, pyridine, pyrimidine
  • a 5-membered aromatic heterocycle containing one sulfur atom e.g., thiophene
  • a benzene ring fused, and the like.
  • aromatic heterocyclic group examples include
  • 2-furyl, 3-furyl) 2-furyl, 3-furyl
  • thienyl e.g., 2-thienyl, 3-thienyl
  • pyridyl e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl
  • pyrimidinyl e.g., 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl
  • pyridazinyl e.g., 3-pyridazinyl, 4-pyridazinyl
  • pyrazinyl e.g., 2-pyrazinyl
  • pyrrolyl e.g., 1-pyrrolyl, 2-pyrrolyl
  • imidazolyl e.g., 1-imidazoly.l, 2-imidazolyl, 4- imidazolyl, 5-imidazolyl
  • pyrazolyl e.g., 1-pyrazolyl, 3- pyrazolyl, 4-pyrazolyl
  • thiazolyl e.g., 2-thiazolyl, 4- thiazolyl, 5-thiazolyl
  • isothiazolyl e.g., 3-isothiazolyl
  • oxazolyl e.g., 2-oxazolyl, 4-oxazolyl, 5-oxazo
  • triazol-4-yl tetrazolyl (e.g., tetrazol-l-yl, tetrazol-5-yl) , triazinyl (e.g., 1, 2, 4-triazin-l-yl, 1, 2, 4-triazin-3-yl) and the like;
  • quinolyl e.g., 2-quinolyl, 3-quinolyl, 4-quinolyl, 6- quinolyl
  • isoquinolyl e.g., 3-isoquinolyl
  • quinazolyl e.g.,
  • 2-quinazolyl, 4-quinazolyl) quinoxalyl (e.g., 2-quinoxalyl, 6-quinoxalyl) , benzofuranyl (e.g., 2-benzofuranyl, 3- benzofuranyl) , benzothienyl (e.g., 2-benzothienyl, 3- benzothienyl) , benzoxazolyl (e.g., 2-benzoxazolyl) ,
  • benzisoxazolyl e.g., 7-benzisoxazolyl
  • benzothiazolyl e.g., 2-benzothiazolyl
  • benzimidazolyl e.g., benzimidazol-l-yl, benzimidazol-2-yl, benzimidazol-5-yl
  • benzotriazolyl e.g., lH-1, 2, 3-benzotriazol-5-yl
  • indolyl e.g., indol-l-yl, indol- 2-yl, indol-3-yl, indol-5-yl
  • indazolyl e.g., lH-indazol-3- yl
  • pyrrolopyrazinyl e.g., lH-pyrrolo [2, 3-b] pyrazin-2-yl, lH-pyrrolo [2, 3-b] pyrazin-2-y
  • thieno [2, 3-b] pyridin-3-yl) imidazopyrazinyl (e.g., 1H- imidazo [4, 5-b] pyrazin-2-yl) , pyrazolopyridinyl (e.g., 1H- pyrazolo [4, 3-c] pyridin-3-yl ) , pyrazolothienyl (e.g., 2H- pyrazolo [3, 4-b] thiophen-2-yl) , pyrazolotriazinyl (e.g.,
  • pyrazolo [5, 1-c] [1, 2, 4] triazin-3-yl) pyridopyridinyl (e.g., pyrido [2, 3-b] pyridin-3-yl)
  • thienopyridyl e.g., thieno [2,3- b] pyridin-3-yl
  • non-aromatic heterocyclic group examples include a 4- to 7-membered . (preferably 5- or 6-menbered) monocyclic non- aromatic heterocyclic group containing, as a ring-constituting atom besides carbon atoms, 1 to 4 hetero atoms selected from an oxygen atom, a sulfur atom and a nitrogen atom, and a fused aromatic heterocyclic group.
  • fused aromatic heterocyclic group examples include a group derived from a fused ring wherein a ring corresponding to the 4- to - 7-membered
  • nitrogen atoms e.g., pyrrole, imidazole, pyrazole, pyrazine, pyridine, pyrimidine
  • a 5-membered aromatic heterocycle containing one sulfur atom e.g., thiophene
  • a benzene ring fused, a group wherein the above-mentioned group is partially saturated, and the like.
  • non-aromatic heterocyclic group examples include
  • azetidinyl e.g., 1- azetidinyl, 2-azetidinyl, 3-azetidinyl
  • pyrrolidinyl e.g., 1-pyrrolidinyl, 2-pyrrolidinyl
  • piperidyl e.g., piperidino, 2-piperidyl, 3-piperidyl, 4-piperidyl
  • morpholinyl e.g., morpholino
  • thiomorpholinyl e.g., thiomorpholino
  • piperazinyl e.g., 1-piperazinyl, 2- piperazinyl, 3-piperazinyl
  • hexamethyleniminyl e.g., hexamethylenimin-l-yl
  • oxazolidinyl e.g., oxazolidin-2-yl
  • thiazolidinyl e.g.
  • imidazolinyl e.g., imidazolin-2-yl, imidazolin-3-yl
  • - dioxolyl e.g., 1, 3-dioxol-4-yl
  • dioxolanyl e.g., 1,3- dioxolan-4-yl
  • dihydrooxadiazolyl e.g., 4, 5-dihydro-l, 2, - oxadiazol-3-yl
  • pyranyl e.g., 4-pyranyl
  • tetrahydropyranyl e . g .
  • tetrahydrofuryl e.g., tetrahydrofuran-3-yl, tetrahydrofuran- 2-yl
  • pyrazolidinyl e.g., pyrazolidin-l-yl, pyrazolidin-3- yl
  • pyrazolinyl e.g., pyrazolin-l-yl
  • tetrahydropyrimidin-l-yl e.g., 2,3- dihydro-lH-1, 2, 3-triazol-l-yl
  • tetrahydrotriazolyl e.g., 2,3- dihydro-lH-1, 2, 3-triazol-l-yl
  • dihydroindolyl e . g . , 2 , 3-dihydro-lH-indol-l-yl
  • dihydroisoindolyl e.g., 1, 3-dihydro-2H-isoindol-2-yl
  • dihydrobenzofuranyl e.g., 2, 3-dihydro-l-benzofuran-5-yl
  • dihydrobenzodioxinyl e.g., 2, 3-dihydro-l, 4-benzodioxinyl
  • dihydrobenzodioxepinyl e.g., 3, 4-dihydro-2H-l, 5- benzodioxepinyl
  • tetrahydrobenzofuranyl e.g., 4,5,6,7- tetrahydro-l-benzofuran-3-yl
  • chromenyl e.g., 4H-chromen-2- yl, 2H-chromen-3-yl
  • dihydrochromenyl e.g., 3, 4-dihydro-2H- chromen-2H- chromeny
  • heterocyclic group of the “optionally substituted heterocyclic group” optionally has 1 to 3 substituents at substitutable positions.
  • substituents include those similar to the substituents that the C 3 -i 0 cycloalkyl group and the like exemplified as the "hydrocarbon group” of the above-mentioned "optionally substituted hydrocarbon group” optionally has.
  • the heterocyclic group is a "non-aromatic heterocyclic group”
  • the substituent further includes an oxo group.
  • the number of the substituents is not less than 2, the respective substituents may be the same or different.
  • optionally substituted hydroxy group examples include a hydroxy group optionally substituted by a substituent selected from a Ci-i 0 alkyl group, a C 2 -io
  • alkenyl group a C3-10 cycloalkyl group, a C3-10 cycloalkenyl group, a C 6 -u aryl group, a C 7 -i 3 aralkyl group, a C 8 -i 3
  • arylalkenyl group a Ci_ 6 alkyl-carbonyl group, a heterocyclic group and the like, each of which is optionally substituted.
  • Ci_i 0 alkyl group examples include those
  • hydrocarbon group of the above-mentioned “optionally substituted hydrocarbon group”.
  • heterocyclic group examples include those similar to the “aromatic heterocyclic group" and “non-aromatic heterocyclic group"
  • heterocyclic group exemplified as the "heterocyclic group” of the above-mentioned “optionally substituted heterocyclic group” .
  • Ci-io alkyl group, C 2 -io alkenyl group, C3-10 cycloalkyl group, C3-10 cycloalkenyl group, C 6 -i4 aryl group, C 7 -i3 aralkyl group, C 8 -i3 arylalkenyl group, Ci_ 6 alkyl-carbonyl group and heterocyclic group optionally have.1 to 3
  • Ci-6 alkyl-carbonyl group include those similar to the substituent that the Ci-10 alkyl group and the like exemplified as the "hydrocarbon group" of the above- mentioned “optionally substituted hydrocarbon group"
  • Examples of the substituent for the C3-10 cycloalkyl group, C3-10 cycloalkenyl group, C6-14 aryl group, C 7 _i 3 aralkyl group and Cs-13 arylalkenyl group include those similar to the substituent that the C3-10 cycloalkyl group and the like exemplified as the "hydrocarbon group" of the above-mentioned "optionally
  • substituted hydrocarbon group optionally has.
  • substituent for the heterocyclic group include those similar to the substituent that the "heterocyclic group" of the above- mentioned “optionally substituted heterocyclic group”
  • heterocyclic group and the like, each of which is optionally substituted.
  • optionally substituted amino group examples include an amino group optionally mono- or di- substituted by substituent ( s ) selected from a Ci-10 alkyl group, a C2-10 alkenyl group, a C3-10 cycloalkyl group, a C3-10
  • cycloalkenyl group a Ce-14 aryl group, a C 7 -i 3 aralkyl group, a Ce-13 arylalkenyl group and a heterocyclic group, each of which is optionally substituted; an acyl group and the like.
  • Ci-10 alkyl group examples include those
  • hydrocarbon group of the above-mentioned “optionally substituted hydrocarbon group”.
  • heterocyclic group examples include those similar to the “aromatic heterocyclic group" and “non-aromatic heterocyclic group"
  • heterocyclic group exemplified as the "heterocyclic group” of the above-mentioned “optionally substituted heterocyclic group”.
  • a 5- or 6-membered monocyclic aromatic heterocyclic group is preferable.
  • the Ci-io alkyl group, C 2 -iq alkenyl group, C3-10 cycloalkyl group, C3-10 cycloalkenyl group, C 6 -i4 aryl group, C7-13 aralkyl group, Cg-13 arylalkenyl group and heterocyclic group optionally have 1 to 3 substituents at substitutable positions. When the number of the substituents is not less than 2, the respective substituents may be the same or different.
  • Examples of the substituent for the Ci-10 alkyl group and C2-10 alkenyl group include those similar to the substituent that the Ci-10 alkyl group and the like exemplified as the
  • substituted hydrocarbon group optionally has.
  • C3-10 cycloalkenyl group, C 6 -i4 aryl group, C7-13 aralkyl group and CB-I3 arylalkenyl group include those similar to the substituent that the C3-10 cycloalkyl ' group and the like exemplified as the "hydrocarbon group" of the above-mentioned "optionally
  • substituted hydrocarbon group optionally has.
  • substituent for the heterocyclic group include those similar to the substituent that the "heterocyclic group" of the above- mentioned “optionally substituted heterocyclic group”
  • substituent for the "optionally substituted amino group” include those similar to the "acyl group” below, which is exemplified as the "substituent” for R 2 .
  • R A is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group
  • R A ' and R B ' are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group
  • R A ' and R B ' form, together with the adjacent nitrogen atom, an optionally substituted nitrogen- containing heterocycle, and the like.
  • R A , R A ' or R B ' examples include those similar to the "optionally substituted hydrocarbon group” and “optionally substituted heterocyclic group", which are exemplified as the "substituent" for R 2 .
  • nitrogen-containing heterocycle of the "optionally substituted nitrogen-containing heterocycle” formed by R A ' and R B ' together with the adjacent nitrogen atom
  • nitrogen-containing heterocycle include a 5- to 7-membered nitrogen-containing heterocycle containing, as a ring-constituting atom besides carbon atoms, at least one nitrogen atom and optionally further containing one or two hetero atoms selected from an oxygen atom, a sulfur atom and a nitrogen atom.
  • nitrogen- containing heterocycle include pyrrolidine, imidazolidine, pyrazolidine, piperidine, piperazine, morpholine,
  • the nitrogen-containing heterocycle optionally has 1 to 5 (preferably 1 or 2) substituents at substitutable positions.
  • substituents include those similar to the substituent that the "heterocyclic group" of the "optionally substituted heterocyclic group", which is exemplified as the "substituent" for R 2 , optionally has.
  • the number of the substituents is not less than 2, the respective substituents may be the same or different.
  • acyl group examples include
  • Ci-6 alkyl-carbonyl group e.g., acetyl
  • a Ci-6 alkyl-carbonyl group optionally substituted by 1 to 3 halogen atoms
  • Ci_6 alkoxy-carbonyl group e.g., methoxycarbonyl
  • a C3-10 cycloalkyl-carbonyl group e.g., cyclopropylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl
  • a C3-10 cycloalkyl-carbonyl group e.g., cyclopropylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl
  • a C 6 -i4 aryl-carbonyl group e.g., benzoyl, 1-naphthoyl, 2- naphthoyl
  • a C 6 -i4 aryl-carbonyl group e.g., benzoyl, 1-naphthoyl, 2- naphthoyl
  • optionally substituted by 1 to 3 halogen atoms e.g., benzoyl, 1-naphthoyl, 2- naphthoyl
  • Ci_6 alkylsulfonyl group e.g., methylsulfonyl
  • an aromatic heterocyclylcarbonyl group e.g., an aromatic heterocyclylcarbonyl group
  • furylcarbonyl, thienylcarbonyl optionally substituted by 1 to 3 substituents selected from a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms;
  • a non-aromatic heterocyclylcarbonyl group e.g.,
  • tetrahydrofurylcarbonyl, pyrrolidinocarbonyl optionally substituted by 1 to 3 substituents selected from a Ci- 6 alkyl group optionally substituted by 1 to 3 halogen atoms;
  • R 2 is preferably an optionally substituted Ci- 6 alkyl group, an optionally substituted Ci_ 6 alkoxy group, an
  • C 3 _io cycloalkyl group an optionally substituted Ce-u aryl group, an optionally substituted amino group, an optionally substituted aromatic heterocyclic group,. an optionally substituted non-aromatic heterocyclic group or the like .
  • R 2 is preferably
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • a Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • Ci-6 alkoxy-carbonyl group e.g., methoxycarbonyl, ethoxycarbonyl
  • Ci-6 alkoxy group e.g., methoxy
  • a halogen atom e.g., a fluorine atom
  • Ci_6 alkoxy group e.g., methoxy, tert-butoxy
  • a C3-10 cycloalkyl group e.g., cyclopropyl, cyclopentyl
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl
  • isopropyl optionally substituted by 1 to 3 C 6 -i 4 aryl groups (e.g., phenyl),
  • a C3-10 cycloalkyl group e.g., cyclopentyl
  • Ci-6 alkylsulfonyl group e.g., methylsulfonyl
  • an aromatic heterocyclic group e.g., pyridyl
  • Ci-6 alkyl groups e.g., methyl
  • an aromatic heterocyclic group e.g., furyl, pyrazolyl, pyridyl, isoxazolyl, thiazolyl.
  • an aromatic heterocyclic group e.g., furyl, pyrazolyl, pyridyl, isoxazolyl, thiazolyl.
  • substituents selected from a Ci_6 alkyl group optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom);
  • a non-aromatic heterocyclic group e.g.,
  • R 2 is more preferably an optionally substituted Ci_ 6 alkyl group, an optionally substituted Ci_6 alkoxy group, an
  • R 2 is more preferably
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • a Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • Ci_6 alkoxy-carbonyl group e.g., methoxycarbonyl, ethoxycarbonyl
  • Ci-6 alkoxy group e.g., methoxy
  • a halogen atom e.g., a fluorine atom
  • Ci-6 alkoxy group e.g., methoxy, tert-butoxy
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl
  • isopropyl optionally substituted by 1 to 3 C6-14 aryl groups (e.g., phenyl),
  • a C3-10 cycloalkyl group e.g., cyclopentyl
  • Ci-6 alkylsulfonyl group e.g., methylsulfonyl
  • an aromatic heterocyclic group e.g., pyridyl
  • Ci_ 6 alkyl groups e.g., methyl
  • R 2 is still more preferably
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • Ci-6 alkoxy group e.g., methoxy, tert-butoxy
  • Ci- 6 alkyl group(s) e.g., methyl, ethyl, propyl, isopropyl
  • R 2 is particularly preferably
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • Ci-6 alkoxy group e.g., methoxy, tert-butoxy
  • Ci_ 6 alkyl group(s) e.g., methyl, ethyl, propyl, isopropyl
  • the "group represented by the formula: -COR 2 " for R 1 is preferably a group represented by the formula: -COR 2 wherein R 2 is an optionally substituted Ci_ 6 alkyl group, an optionally substituted Ci_ 6 alkoxy group, an optionally substituted C 3 -i 0 cycloalkyl group, an optionally substituted C 6 -i 4 aryl group, an optionally substituted amino group, an optionally substituted aromatic heterocyclic group, an optionally substituted non- aromatic heterocyclic group or the like.
  • the "group represented by the formula: - COR 2 " for R 1 is preferably a group represented by the formula: -COR 2 wherein
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • a Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • Ci-6 alkoxy-carbonyl group e.g., methoxycarbonyl, ethoxycarbonyl
  • Ci-6 alkoxy group e.g., methoxy
  • a halogen atom e.g., a fluorine atom
  • Ci-6 alkoxy group e.g., methoxy, tert-butoxy
  • a C3-10 cycloalkyl group e.g., cyclopropyl
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, isopropyl
  • aryl groups e.g., phenyl
  • a C3-10 cycloalkyl group e.g., cyclopentyl
  • Ci-6 alkylsulfonyl group e.g., methylsulfonyl
  • an aromatic heterocyclic group e.g., pyridyl
  • Ci-6 alkyl groups e.g., methyl
  • an aromatic heterocyclic group e.g., furyl, . pyrazolyl, pyridyl, isoxazolyl, thiazolyl
  • an aromatic heterocyclic group e.g., furyl, . pyrazolyl, pyridyl, isoxazolyl, thiazolyl
  • 1 to 3 substituents selected from a Ci_ 6 alkyl group optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom) ;
  • a non-aromatic heterocyclic group e.g., tetrahydropyranyl
  • the "group represented by the formula: -COR 2 " for R 1 is more preferably a group represented by the formula: -COR 2 wherein R 2 is an optionally substituted Ci_ 6 alkyl group, an optionally substituted Ci_ 6 alkoxy group, an optionally
  • COR 2 " for R 1 is more preferably a group represented by the formula: -COR 2
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • a Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • Ci-6 alkoxy-carbonyl group e.g., methoxycarbonyl, ethoxycarbonyl
  • Ci-6 alkoxy group e.g., methoxy
  • a halogen atom e.g., a fluorine atom
  • Ci-6 alkoxy group e.g., methoxy, tert-butoxy
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, isopropyl
  • 1 to 3 C 6 -i4 aryl groups e.g., phenyl
  • a C3-10 cycloalkyl group e.g., cyclopentyl
  • Ci-6 alkylsulfonyl group e.g., methylsulfonyl
  • an aromatic heterocyclic group e.g., pyridyl
  • 1 to 3 Ci-6 alkyl groups e.g., methyl
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • Ci-6 alkoxy group e.g., methoxy, tert-butoxy
  • Ci- alkyl group(s) e.g., methyl, ethyl, propyl, isopropyl
  • the "group represented by the formula: -COR 2 " for R 1 is particularly preferably a group represented by the formula: - COR 2
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • Ci-6 alkoxy group e.g., methoxy, tert-butoxy
  • Ci- alkyl group(s) e.g., methyl, ethyl, propyl, isopropyl
  • Examples of the "5- or 6-membered aromatic group" of the "optionally substituted 5- or 6-membered aromatic group” for R include phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl (1,2,3-triazolyl, 1, 2, 4-triazolyl, 1, 3, 4-triazolyl) ,
  • tetrazolyl oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, furyl, thienyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl and the like.
  • the "5- or 6-membered aromatic group” is preferably a 5- membered aromatic heterocyclic group, phenyl or the like, more preferably pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, phenyl or the like, particularly preferably isoxazolyl.
  • the "5- or 6-membered aromatic group" of the "optionally substituted 5- or 6-membered aromatic group” for R 1 optionally has 1 to 3 substituents at substitutable positions.
  • substituents include those similar to the substituents that the C 3 -i 0 cycloalkyl group and the like exemplified as the "hydrocarbon group” of the “optionally substituted hydrocarbon group", which is exemplified as the "substituent” for R 2 , optionally has.
  • the "optionally substituted 5- or 6-membered aromatic group" for R 1 is preferably a 5-membered aromatic heterocyclic group (e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, preferably isoxazolyl) or phenyl, each of which is optionally substituted by 1 to 3 substituents selected from
  • Ci-6 alkyl-carbonyl group optionally substituted by 1 to 3 halogen atoms
  • Ci-6 alkoxy-carbonyl group optionally substituted by 1 to 3 substituents selected from
  • Ci-6 alkyl group optionally substituted by 1 to 3 substituents selected from
  • the "optionally substituted 5- or 6-membered aromatic group" for R 1 is more preferably a 5-membered aromatic
  • heterocyclic group e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, preferably isoxazolyl
  • phenyl each of which is optionally substituted by 1 to 3 substituents selected from (i) a halogen atom and (ii) a Ci-6 alkyl group.
  • the "optionally substituted 5- or 6-membered aromatic group" for R 1 is still more preferably a 5-membered aromatic heterocyclic group (e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, preferably isoxazolyl) optionally substituted by 1 to 3 substituents selected from a Ci-6 alkyl group.
  • a 5-membered aromatic heterocyclic group e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, preferably isoxazolyl
  • R 1 is preferably
  • R 2 is an optionally substituted Ci- 6 alkyl group, an optionally
  • Ci- 6 alkoxy group an optionally substituted C 3 -i 0 cycloalkyl group, an optionally substituted C 6 -i4 aryl group, an optionally substituted amino group, an optionally substituted aromatic heterocyclic group, an optionally substituted non- aromatic heterocyclic group or the like; or
  • R 1 is preferably (1) a group represented by the formula: -COR 2
  • R 2 is ⁇
  • a C-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • a C-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • Ci-6 alkoxy-carbonyl group e.g., methoxycarbonyl, ethoxycarbonyl
  • Ci-6 alkoxy group e.g., methoxy
  • a halogen atom e.g., a fluorine atom
  • Ci-6 alkoxy group e.g., methoxy, tert-butoxy
  • a C3-10 cycloalkyl group e.g., cyclopropyl
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, isopropyl
  • 1 to 3 C 6 -i4 aryl groups e.g., phenyl
  • a C3-10 cycloalkyl group e.g., cyclopentyl
  • Ci-6 alkylsulfonyl group e.g., methylsulfonyl
  • an aromatic heterocyclic group e.g., pyridyl
  • Ci- 6 alkyl groups e.g., methyl
  • an aromatic heterocyclic group e.g., furyl, pyrazolyl, pyridyl, isoxazolyl, thiazolyl
  • an aromatic heterocyclic group e.g., furyl, pyrazolyl, pyridyl, isoxazolyl, thiazolyl
  • 1 to 3 substituents selected from a Ci_ 6 alkyl group optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine
  • a 5-membered aromatic heterocyclic group e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, preferably isoxazolyl
  • phenyl each of which is optionally substituted by 1 to 3 substituents selected from
  • Ci_6 alkyl-carbonyl group optionally substituted by 1 to 3 halogen atoms
  • Ci_ 6 alkoxy-carbonyl group optionally substituted by 1 to 3 substituents selected from
  • Ci-6 alkyl group optionally substituted by 1 to 3 substituents selected from
  • R 1 is more preferably
  • R 2 is an optionally substituted C-6 alkyl group, an optionally
  • Ci- 6 alkoxy group an optionally substituted, amino group or the like;
  • R 1 is more preferably
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • a Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • Ci-6 alkoxy-carbonyl group e.g., methoxycarbonyl, ethoxycarbonyl
  • a C6-1 aryl group e.g., phenyl
  • Ci-6 alkoxy group e.g., methoxy
  • a halogen atom e.g., a fluorine atom
  • Ci-6 alkoxy group e.g., methoxy, tert-butoxy
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, isopropyl
  • aryl groups e.g., phenyl
  • a C3-10 cycloalkyl group e.g., cyclopentyl
  • Ci-6 alkylsulfonyl group e.g., methylsulfonyl
  • a 5-membered aromatic heterocyclic group e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, preferably isoxazolyl
  • phenyl each of which is optionally substituted by 1 to 3 substituents selected from (i) a halogen atom and (ii) a Ci-6 alkyl group.
  • R 1 is further more preferably
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • Ci-6 alkoxy group e.g., methoxy, tert-butoxy
  • Ci- alkyl group(s) e.g., methyl, ethyl, propyl, isopropyl; or the like; or
  • a 5-membered aromatic heterocyclic group e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, preferably isoxazolyl
  • a 5-membered aromatic heterocyclic group e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, preferably isoxazolyl
  • R 1 is still more preferably
  • Ci_6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • Ci_6 alkoxy group e.g., methoxy, tert-butoxy
  • Ci_ alkyl group (s) e.g., methyl, ethyl, propyl, isopropyl
  • R 1 is particularly preferably
  • Ci_6 alkyl group e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl
  • Ci-6 alkoxy group e.g., methoxy, tert-butoxy
  • Ci- 6 alkyl group e.g., methyl, ethyl, propyl, isopropyl
  • ring P is an optionally further substituted 5-membered aromatic ring
  • ring Q is an optionally further substituted 6- membered ring
  • ring P and ring Q are fused to form an optionally further substituted bicyclic aromatic ring, or
  • ring P is an optionally further substituted 5-membered non-aromatic ring
  • ring Q is an optionally further substituted 6-membered aromatic ring
  • ring P and ring Q are fused to form an optionally further substituted bicyclic non-aromatic ring.
  • ring P is an optionally further substituted 5-membered aromatic ring
  • ring Q is an optionally further substituted 6- membered ring
  • ring P and ring Q are fused to form an optionally further substituted bicyclic aromatic ring
  • "optionally further substituted 5-membered aromatic ring" for ring P include pyrrole, pyrazole, imidazole, triazole (1,2,3- triazole, 1, 2, 4-triazole, 1, 3, 4-triazole) , tetrazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, thiadiazole, furan, thiophene and the like. Of these, oxazole, thiazole, pyrazole and 1, 2, 3-triazole are preferable, and pyrazole, oxazole and thiazole are particularly preferable.
  • the "5-membered aromatic ring" of the "optionally further substituted 5-membered aromatic ring” for ring P optionally has 1 or 2 substituents, besides ring A, at substitutable position.
  • substituents include those similar to the substituents that the C3-10 cycloalkyl group and the like exemplified as the "hydrocarbon group” of the “optionally substituted hydrocarbon group", which is exemplified as the "substituent” for R 2 , optionally has.
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci-6 alkyl group e.g., methyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • a C 3 -6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • Examples of the "6-membered ring" of the "optionally further substituted 6-membered ring” for ring Q include benzene, pyridine, pyridazine, pyrimidine, pyrazine, triazine, cyclohexa-1, 3-diene, dihydropyridine and the like. Of these, benzene, 1, 2-dihydropyridine and cyclohexa-1, 3-diene are particularly preferable.
  • substituted 6-membered ring for ring Q optionally has, besides the group -O-R 6 , 1 to 3 substituents at substitutable positions.
  • substituents include those similar to the substituents that the C3-10 cycloalkyl group and the like exemplified as the "hydrocarbon group” of the "optionally substituted hydrocarbon ' group", which is exemplified as the "substituent” for R 2 , optionally has.
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci-6 alkyl group e.g., methyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • a C3-6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • the "bicyclic aromatic ring" of the "optionally further substituted bicyclic aromatic ring” formed by fusion of ring P and ring Q optionally has, besides the group of R 6 -0-, 1 to 3 substituents at substitutable positions on the ring Q, and optionally has, besides ring A, . 1 or 2 substituents at substitutable positions on the ring P.
  • substituents include those similar to the substituents that the C3-10 cycloalkyl group and the like exemplified as the
  • hydrocarbon group of the "optionally substituted hydrocarbon group”, which is exemplified as the "substituent” for R 2 , optionally has.
  • substituted bicyclic aromatic ring formed by fusion of ring P and ring Q include
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci-6 alkyl group e.g., methyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • a C3-6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • the "optionally further substituted bicyclic aromatic ring" formed by fusion of ring P and ring Q is preferably
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci-6 alkyl group e.g., methyl
  • halogen atoms e.g., a fluorine atom
  • C 3 -6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • the "optionally further substituted bicyclic aromatic heterocycle" formed by fusion of ring P and ring Q . is more preferably
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci- 6 alkyl group e.g., methyl
  • halogen atoms e.g., a fluorine atom
  • a C3-6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci-6 alkyl group e .g. , methyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • a C3-6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • (2) ring P is an optionally further substituted 5-membered non-aromatic ring
  • ring Q is an optionally further substituted 6-membered aromatic ring
  • ring P and ring Q are fused to form an optionally further substituted bicyclic non-aromatic - ring.
  • ring P optionally further substituted 5-membered non-aromatic ring
  • ring P include cyclopentene, dihydrofuran,
  • the "5-membered non-aromatic ring" of the "optionally further substituted 5-membered non-aromatic ring" for ring P optionally has, besides ring A, 1 to 5 substituents at
  • substituents include those similar to the substituents that the C3-10 cycloalkyl group and the like exemplified as the "hydrocarbon group” of the “optionally substituted hydrocarbon group", which is exemplified as the "substituent” for R 2 ., optionally has.
  • substituted 5-membered non-aromatic ring for ring P include
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci-6 alkyl group e.g., methyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • a C3-6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • ring Q optionally further substituted 6-membered aromatic ring
  • ring Q include benzene, pyridine, pyridazine, pyrimidine, pyrazine, triazine and the like.
  • the "6-membered aromatic ring" of the "optionally further substituted 6-membered aromatic ring" for ring Q optionally has, besides the group R 6 -0-, 1 to 3 substituents at
  • substituents include those similar to the substituents that the C3-10 cycloalkyl group and the like exemplified as the "hydrocarbon group” of the “optionally substituted hydrocarbon group", which is exemplified as the "substituent” for R 2 , optionally has.
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci-6 alkyl group e.g., methyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • a C3-6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • bicyclic non-aromatic ring of the "optionally further substituted bicyclic non-aromatic ring” formed by fusion of ring P and ring Q optionally has, besides ring A, 1 to 5 substituents at substitutable positions on the ring P, and optionally has, besides the group -O-R 6 , 1 to 3
  • substituents include those similar to the substituents that the C3-10 cycloalkyl group and the like exemplified as the "hydrocarbon group” of the “optionally substituted hydrocarbon group", which is exemplified as the "substituent” for R 2 , optionally has.
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci- 6 alkyl group e.g., methyl
  • halogen atoms e.g., a fluorine atom
  • a C3-6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • the "optionally further substituted bicyclic non-aromatic ring" formed by fusion of ring P and ring Q is preferably
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci-6 alkyl group (e.g., methyl) optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom),
  • a C3-6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • the "optionally further substituted bicyclic non-aromatic ring" formed by fusion of ring P and ring Q is more preferably [0139] [0140]
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci-6 alkyl group e.g., methyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • a C 3 -6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • the "optionally further substituted bicyclic non-aromatic ring" formed by fusion of ring P and ring Q is still more preferably
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • a C1-6 alkyl group e.g., methyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • a C3-6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci-6 alkyl group e.g., methyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • a C 3 -6 cycloalkyl group e.g., cyclopropyl
  • a halogen atoms e.g., a fluorine atom
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci-6 alkyl group e.g., methyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • a C 3 -6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • a halogen atom e.g., a fluorine atom, a chlorine atom, a bromine atom
  • Ci- 6 alkyl group e.g., methyl
  • halogen atoms e.g., a fluorine atom
  • a C 3 -6 cycloalkyl group e.g., cyclopropyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • R 3 is a Ci-6 alkyl group optionally substituted by halogen atom(.s), or an optionally substituted C3-6 cycloalkyl group.
  • the "Ci-6 alkyl group" of the "Ci- 6 alkyl group optionally substituted by halogen atom(s)" for R 3 optionally has
  • C3-6 cycloalkyl group" of the “optionally substituted C3-6 cycloalkyl group” for R 3 include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • C3-6 cycloalkyl group" of the "optionally substituted C 3 -6 cycloalkyl group” for R 3 optionally has 1 to.7 substituents at substitutable positions.
  • substituents include those similar to the substituents that the C3-10
  • R 3 is preferably a Ci-6 alkyl group optionally substituted by 1 to 7 (preferably 1 to 3) halogen atoms (e.g., a fluorine atom) , or a C 3 _ 6 cycloalkyl group, more preferably a Ci_ 6 alkyl group optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom) , still more preferably a Ci-6 alkyl group, particularly preferably methyl.
  • 1 to 7 preferably 1 to 3 halogen atoms
  • C 3 _ 6 cycloalkyl group more preferably a Ci_ 6 alkyl group optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom) , still more preferably a Ci-6 alkyl group, particularly preferably methyl.
  • R a and R 4b are independently a hydrogen atom or a
  • Examples of the "substituent" for R 4a or R 5b include those similar to the "substituent" for R 2 .
  • R 4a is preferably a hydrogen atom or a fluorine atom, particularly preferably a hydrogen atom.
  • R 4b is preferably a hydrogen atom or a fluorine atom, particularly preferably a hydrogen atom.
  • X is 0, CO, CR 5a R 5b wherein R 5a and R 5b are independently a hydrogen atom or a substituent, NR 5c wherein R 5c is a hydrogen atom or an optionally substituted Ci-6 alkyl group, S, SO or S(0) 2 .
  • Examples of the "substituent" for R 5a or R 5b include those similar to the "substituent” for R 2 .
  • Ci-6 alkyl group of the "optionally substituted Ci_ 6 alkyl group” for R 5c optionally has 1 to 3 substituents at substitutable positions.
  • substituents include those similar to the substituents that the Ci-10 alkyl group and the like exemplified as the "hydrocarbon group" of the
  • X is preferably 0, CO or CR 5a R 5b wherein R 5a and R 5b are the same as above, more preferably 0, CO or CH 2 , particularly preferably 0.
  • R 6 is an optionally substituted Ci_ 6 alkyl group or an optionally substituted C 3 _ 6 cycloalkyl group.
  • Ci-6 alkyl group of the "optionally substituted Ci- 6 alkyl group” for R 6 optionally has 1 to 3 substituents at .
  • substituents include those similar to the substituents that the Ci_i 0 alkyl group and the like exemplified as the "hydrocarbon group" of the
  • R 6 is preferably
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, isopropyl, butyl
  • a Ci-6 alkyl group optionally substituted by 1 to 3 substituents selected from
  • halogen atom e.g., a fluorine* atom
  • a C 3 -6 cycloalkyl group e.g., cyclopropyl, cyclobutyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • R 6 is more ' preferably a Ci_ 6 alkyl group (e.g., methyl, ethyl, propyl, isopropyl, butyl) optionally substituted by 1 to 3 substituents selected from
  • halogen atom e.g., a fluorine atom
  • a C 3 -6 cycloalkyl group e.g., cyclopropyl, cyclobutyl
  • 1 to 3 halogen atoms e.g., a fluorine atom
  • R 6 is still more preferably a Ci_ 6 alkyl group optionally substituted by 1 to 3 C 3 - 6 cycloalkyl groups optionally
  • R 6 is preferably a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms.
  • Ring A is an optionally further substituted 5- or 6- membered aromatic ring.
  • Examples of the "5- or 6-membered aromatic ring" of the "optionally further substituted 5- or 6-membered aromatic ring” for ring A include benzene, pyrrole, pyrazole, imidazole, triazole ( 1, 2 , 3-triazole, 1 ,2 , 4-triazole, 1, 3, -triazole) , tetrazole, oxazole, isoxazole, thiazole, isothiazole,
  • oxadiazole (1, 2, 4-oxadiazole, 1, 3, 4-oxadiazole)
  • thiadiazole (1, 2, -thiadiazole, 1, 3, 4-thiadiazole)
  • furan, thiophene pyridine, pyridazine, pyrimidine, pyrazine, triazine and the like .
  • the "5- or 6-membered aromatic ring" of the "optionally further substituted 5- or 6-membered aromatic ring" for ring A is preferably benzene, optionally oxidized pyridine,
  • benzene optionally oxidized pyridine, pyrimidine, pyrazole, isoxazole or oxadiazole, still more preferably
  • benzene optionally oxidized pyridine, pyrimidine, pyrazole or isoxazole.
  • the "5- or 6-membered aromatic ring" of the "optionally further substituted 5- or 6-membered aromatic ring" for ring A optionally has, besides group -X-CH (R 4a ) (R 4b ) -CH (R 3 ) -NH-R 1 and ring P, 1 to 4 substituents (preferably 1 to 3 substituents) at substitutable positions. Examples of the substituent
  • heterocyclic group which is exemplified as the "substituent" for R 2 , optionally has.
  • Ring A is preferably benzene, optionally oxidized
  • a halogen atom e.g., a fluorine atom, a chlorine atom
  • Ci-6 alkyl group e.g., methyl
  • halogen atoms e.g., n-butane
  • Ci-6 alkoxy group e.g., methoxy
  • a C 7 -i3 aralkyl group e.g., benzyl
  • Ring A is more preferably benzene, optionally oxidized pyridine, pyrimidine, pyrazole, isoxazole or oxadiazole, each of which is optionally substituted by 1 to 3 substituents selected from
  • a halogen atom e.g., a fluorine atom, a chlorine atom
  • Ci-6 alkyl group e.g., methyl
  • halogen atoms e.g., n-butane
  • Ci-6 alkoxy group e.g., methoxy
  • a C 7 -i3 aralkyl group e.g., benzyl
  • Ring A is still more preferably benzene, optionally oxidized pyridine, pyrimidine, pyrazole or isoxazole, each of which is optionally substituted by 1 to 3 substituents
  • halogen atom e.g., a fluorine atom, a chlorine atom
  • Ci-6 alkyl group e.g., methyl
  • Ci-6 alkoxy group e.g., methoxy
  • a C 7 -i3 aralkyl group e.g., benzyl
  • compound (I) include the following compounds .
  • R 2 is an optionally substituted Ci_ 6 alkyl group, an optionally
  • Ci_6 alkoxy group an optionally substituted C3-10 cycloalkyl group, an optionally substituted C 6 -i 4 aryl group, an optionally substituted amino group, an optionally substituted aromatic heterocyclic group or an optionally substituted non- aromatic heterocyclic group; or
  • R 3 is a Ci_6 alkyl group optionally substituted by 1 to 7 halogen atoms, or a C3-6 cycloalkyl group;
  • R a and R b are independently a hydrogen atom or a fluorine atom
  • X is 0, CO, CR 5a R 5b wherein R 5a and R 5b is as defined above, NR 5c wherein R 5c is as defined above, S, SO or S(0) 2 ;
  • ring A is benzene, pyridine, pyrazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole or thiadiazole, each of which is optionally substituted by
  • a halogen atom e.g., a fluorine atom, a chlorine atom
  • Ci-6 alkyl group e.g., methyl
  • halogen atoms optionally substituted by 1 to 3 halogen atoms
  • a halogen atom e.g., a fluorine atom, a chlorine atom
  • Ci-6 alkyl group optionally substituted by halogen .
  • Ci-6 alkyl group optionally substituted by 1 to 3
  • Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isdbutyl, isopentyl
  • a' Ci-6 alkyl group e.g., methyl, ethyl, propyl, butyl, isdbutyl, isopentyl
  • Ci-6 alkoxy-carbonyl group e.g., methoxycarbonyl, ethoxycarbonyl
  • Ci-6 alkoxy group e.g., methoxy
  • Ci-6 alkoxy group e.g., methoxy, tert-butoxy
  • Ci_6 alkyl group e.g., methyl, ethyl, propyl, isopropyl
  • aryl groups e.g., phenyl
  • a C3-10 cycloalkyl group e.g., cyclopentyl
  • Ci-6 alkylsulfonyl group e.g methylsulfonyl
  • an aromatic heterocyclic group e.g., pyridyl
  • Ci-6 alkyl groups e.g • r methyl
  • a 5-membered aromatic heterocyclic group e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl
  • phenyl each of which is optionally substituted by 1 to 3 substituents selected from (i) a halogen atom and (ii) a Ci- 6 alkyl group;
  • R 3 is a Ci-6 alkyl group optionally substituted by 1 to 7
  • R a and R b are independently a hydrogen atom or a fluorine atom
  • X is 0 or CH 2 ;
  • ring A is benzene, pyridine, pyrazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole or thiadiazole, each of which is optionally substituted by
  • a halogen atom e.g., a fluorine atom, a chlorine atom
  • Ci-6 alkyl group e.g.> methyl
  • halogen atoms optionally substituted by 1 to 3 halogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PCT/JP2011/078010 2010-11-30 2011-11-29 Bicyclic compound Ceased WO2012074126A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
EA201390794A EA201390794A1 (ru) 2010-11-30 2011-11-29 Бициклическое соединение
BR112013013417A BR112013013417A2 (pt) 2010-11-30 2011-11-29 composto, medicamento, métodos para inibir a acetil-coa carboxilase em um mamífero, e de profilaxia ou tratamento da obesidade ou diabete em um mamífero, e, uso de um composto ou sal
SG2013041546A SG190925A1 (en) 2010-11-30 2011-11-29 Bicyclic compound
AU2011337565A AU2011337565A1 (en) 2010-11-30 2011-11-29 Bicyclic compound
CN201180066388.XA CN103347872B (zh) 2010-11-30 2011-11-29 双环化合物
PH1/2013/501099A PH12013501099A1 (en) 2010-11-30 2011-11-29 Bicyclic compound
EP11802168.2A EP2649062B1 (en) 2010-11-30 2011-11-29 Bicyclic compounds as inhibitors of acetyl-coa carboxylase (acc)
KR1020137016850A KR20140001965A (ko) 2010-11-30 2011-11-29 바이시클릭 화합물
JP2013524677A JP5824517B2 (ja) 2010-11-30 2011-11-29 二環性化合物
ES11802168.2T ES2536319T3 (es) 2010-11-30 2011-11-29 Compuestos bicíclicos como inhibidores de acetil-CoA carboxilasa (ACC)
CA2819400A CA2819400A1 (en) 2010-11-30 2011-11-29 Bicyclic compound
MX2013006113A MX2013006113A (es) 2010-11-30 2011-11-29 Compuestos biciclico.
TNP2013000230A TN2013000230A1 (en) 2011-08-10 2013-05-29 Bicyclic compound
MA35965A MA34713B1 (fr) 2010-11-30 2013-06-05 Compose bicyclique

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2010266097 2010-11-30
JP2010-266097 2010-11-30
JP2011175330 2011-08-10
JP2011-175330 2011-08-10

Publications (2)

Publication Number Publication Date
WO2012074126A1 true WO2012074126A1 (en) 2012-06-07
WO2012074126A9 WO2012074126A9 (en) 2013-06-06

Family

ID=45418740

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/078010 Ceased WO2012074126A1 (en) 2010-11-30 2011-11-29 Bicyclic compound

Country Status (24)

Country Link
US (1) US8729102B2 (enExample)
EP (1) EP2649062B1 (enExample)
JP (1) JP5824517B2 (enExample)
KR (1) KR20140001965A (enExample)
CN (1) CN103347872B (enExample)
AR (1) AR084032A1 (enExample)
AU (1) AU2011337565A1 (enExample)
BR (1) BR112013013417A2 (enExample)
CA (1) CA2819400A1 (enExample)
CL (1) CL2013001520A1 (enExample)
CO (1) CO6751239A2 (enExample)
CR (1) CR20130281A (enExample)
DO (1) DOP2013000118A (enExample)
EA (1) EA201390794A1 (enExample)
EC (1) ECSP13012719A (enExample)
ES (1) ES2536319T3 (enExample)
MA (1) MA34713B1 (enExample)
MX (1) MX2013006113A (enExample)
PE (1) PE20140161A1 (enExample)
PH (1) PH12013501099A1 (enExample)
SG (1) SG190925A1 (enExample)
TW (1) TW201242951A (enExample)
UY (1) UY33756A (enExample)
WO (1) WO2012074126A1 (enExample)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703758B2 (en) 2010-04-27 2014-04-22 Takeda Pharmaceutical Company Limited Bicyclic compound
CN104193731A (zh) * 2014-08-27 2014-12-10 广东东阳光药业有限公司 新型脲取代联苯类化合物及其组合物及用途
WO2015036892A1 (en) 2013-09-12 2015-03-19 Pfizer Inc. Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris
WO2015097713A1 (en) 2013-11-14 2015-07-02 Cadila Healthcare Limited Novel heterocyclic compounds
US9133129B2 (en) 2011-10-24 2015-09-15 Takeda Pharmaceutical Company Limited Bicyclic compound
CN105008348A (zh) * 2013-03-14 2015-10-28 赛隆制药股份公司 吡唑基苯并[d]咪唑衍生物
CN105601626A (zh) * 2015-11-04 2016-05-25 浙江大学 一种含2-取代噁唑啉衍生物的制备方法
EP2928473A4 (en) * 2012-12-07 2016-06-08 Merck Sharp & Dohme REGIOSELECTIVE N-2-ARYLATION OF INDAZOLES
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
CN104447725B (zh) * 2014-10-22 2018-02-02 浙江大学 一种手性含亚胺吡啶噁唑啉的化合物及其制备方法
US10065963B2 (en) 2015-11-06 2018-09-04 Incyte Corporation Heterocyclic compounds as PI3K-γ inhibitors
US10138248B2 (en) 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
US10233156B2 (en) 2015-03-30 2019-03-19 Shionogi & Co., Ltd. 9-membered fused ring derivative
EP3355699A4 (en) * 2015-09-29 2019-06-19 OncoTherapy Science, Inc. BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITION OF SUV39H2
US10738057B2 (en) 2017-10-18 2020-08-11 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
US11059836B2 (en) 2014-08-29 2021-07-13 Chdi Foundation, Inc. Probes for imaging huntingtin protein
US11161834B2 (en) 2017-04-24 2021-11-02 Tesaro, Inc. Methods of manufacturing of niraparib
US11186580B2 (en) 2018-09-05 2021-11-30 Incyte Corporation Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor
US11352340B2 (en) 2016-01-05 2022-06-07 Incyte Corporation Pyridine and pyridimine compounds as PI3K-gamma inhibitors
WO2023090411A1 (ja) 2021-11-19 2023-05-25 塩野義製薬株式会社 心疾患または骨格筋の疾患の治療用医薬
WO2023217989A1 (en) 2022-05-12 2023-11-16 Syngenta Crop Protection Ag Alkoxy heteroaryl- carboxamide or thioamide compounds
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds
WO2024126650A1 (en) 2022-12-15 2024-06-20 Syngenta Crop Protection Ag Novel bicyclic-carboxamide compounds useful as pesticides

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014262636A1 (en) 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
WO2014182945A1 (en) * 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
MX2015015421A (es) 2013-05-10 2016-06-21 Nimbus Apollo Inc Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
US10208044B2 (en) 2013-05-10 2019-02-19 Gilead Apollo, Llc ACC inhibitors and uses thereof
SG11201700777VA (en) 2014-08-04 2017-02-27 Nuevolution As Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
JP2021098692A (ja) 2019-12-20 2021-07-01 ヌエヴォリューション・アクティーゼルスカブNuevolution A/S 核内受容体に対して活性の化合物
US11685727B2 (en) 2019-12-20 2023-06-27 Nuevolution A/S Compounds active towards nuclear receptors
JP7713954B2 (ja) 2020-03-31 2025-07-28 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物
MX2022012260A (es) 2020-03-31 2022-11-30 Nuevolution As Compuestos activos frente a receptores nucleares.

Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
WO2001014372A2 (en) 1999-08-25 2001-03-01 Takeda Chemical Industries, Ltd. Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent
WO2001082925A1 (en) 2000-04-28 2001-11-08 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonists
WO2001087834A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
WO2002006234A1 (en) 2000-07-17 2002-01-24 Takeda Chemical Industries, Ltd. Sulfone derivatives, process for their production and use thereof
WO2004039365A1 (en) 2002-11-01 2004-05-13 Takeda Pharmaceutical Company Limited Agent for preventing or treating neuropathy
WO2004041266A1 (ja) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited 受容体機能調節剤
WO2004048363A1 (ja) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited イミダゾール誘導体、その製造法および用途
WO2004106276A1 (ja) 2003-05-30 2004-12-09 Takeda Pharmaceutical Company Limited 縮合環化合物
WO2005030740A1 (ja) 2003-09-30 2005-04-07 Takeda Pharmaceutical Company Limited チアゾリン誘導体およびその用途
WO2005058823A1 (ja) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited ウレア誘導体、その製造法及び用途
WO2005063729A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
WO2005095338A1 (ja) 2004-03-30 2005-10-13 Takeda Pharmaceutical Company Limited アルコキシフェニルプロパン酸誘導体
WO2005113504A1 (en) 2004-05-21 2005-12-01 Takeda Pharmaceutical Company Limited Cyclic amide derivatives, and their production and use as antithrombotic agents
WO2006112549A1 (ja) 2005-04-20 2006-10-26 Takeda Pharmaceutical Company Limited 縮合複素環化合物
WO2007013694A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited フェノキシアルカン酸化合物
WO2007013689A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited シクロプロパンカルボン酸化合物
WO2007018314A2 (en) 2005-08-10 2007-02-15 Takeda Pharmaceutical Company Limited Therapeutic agent for diabetes
WO2007028135A2 (en) 2005-09-01 2007-03-08 Takeda Pharmaceutical Company Limited Imidazopyridine compounds
WO2008001931A2 (en) 2006-06-27 2008-01-03 Takeda Pharmaceutical Company Limited Fused cyclic compounds
WO2008047821A1 (en) 2006-10-18 2008-04-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2008050821A1 (en) 2006-10-19 2008-05-02 Takeda Pharmaceutical Company Limited Indole compound
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
WO2008099794A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of ppar-gamma
WO2008136428A1 (ja) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited 含窒素5員複素環化合物
WO2008156757A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
WO2010050445A1 (ja) 2008-10-27 2010-05-06 武田薬品工業株式会社 二環性化合物
WO2011136385A1 (en) 2010-04-27 2011-11-03 Takeda Pharmaceutical Company Limited Bicyclic compound derivatives and their use as acc inhibitors.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69828522T2 (de) * 1997-04-30 2005-12-15 Eli Lilly And Co., Indianapolis Antithrombotische mittel
ES2385378T3 (es) * 2002-07-24 2012-07-24 Dermira (Canada), Inc. Derivados de pirazolilbenzotiazol y su uso como agentes terapéuticos
EP1996567B1 (en) * 2006-02-15 2013-09-18 AbbVie Inc. Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
US8927576B2 (en) * 2009-04-06 2015-01-06 PTC Therpeutics, Inc. HCV inhibitor and therapeutic agent combinations
WO2012108478A1 (ja) 2011-02-09 2012-08-16 武田薬品工業株式会社 単環化合物

Patent Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
WO2001014372A2 (en) 1999-08-25 2001-03-01 Takeda Chemical Industries, Ltd. Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent
WO2001082925A1 (en) 2000-04-28 2001-11-08 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonists
WO2001087834A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
WO2002006234A1 (en) 2000-07-17 2002-01-24 Takeda Chemical Industries, Ltd. Sulfone derivatives, process for their production and use thereof
WO2004039365A1 (en) 2002-11-01 2004-05-13 Takeda Pharmaceutical Company Limited Agent for preventing or treating neuropathy
WO2004041266A1 (ja) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited 受容体機能調節剤
WO2004048363A1 (ja) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited イミダゾール誘導体、その製造法および用途
WO2004106276A1 (ja) 2003-05-30 2004-12-09 Takeda Pharmaceutical Company Limited 縮合環化合物
WO2005030740A1 (ja) 2003-09-30 2005-04-07 Takeda Pharmaceutical Company Limited チアゾリン誘導体およびその用途
WO2005058823A1 (ja) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited ウレア誘導体、その製造法及び用途
WO2005063729A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
WO2005095338A1 (ja) 2004-03-30 2005-10-13 Takeda Pharmaceutical Company Limited アルコキシフェニルプロパン酸誘導体
WO2005113504A1 (en) 2004-05-21 2005-12-01 Takeda Pharmaceutical Company Limited Cyclic amide derivatives, and their production and use as antithrombotic agents
WO2006112549A1 (ja) 2005-04-20 2006-10-26 Takeda Pharmaceutical Company Limited 縮合複素環化合物
WO2007013694A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited フェノキシアルカン酸化合物
WO2007013689A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited シクロプロパンカルボン酸化合物
WO2007018314A2 (en) 2005-08-10 2007-02-15 Takeda Pharmaceutical Company Limited Therapeutic agent for diabetes
WO2007028135A2 (en) 2005-09-01 2007-03-08 Takeda Pharmaceutical Company Limited Imidazopyridine compounds
WO2008001931A2 (en) 2006-06-27 2008-01-03 Takeda Pharmaceutical Company Limited Fused cyclic compounds
WO2008047821A1 (en) 2006-10-18 2008-04-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2008050821A1 (en) 2006-10-19 2008-05-02 Takeda Pharmaceutical Company Limited Indole compound
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
WO2008099794A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of ppar-gamma
WO2008136428A1 (ja) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited 含窒素5員複素環化合物
WO2008156757A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
WO2010050445A1 (ja) 2008-10-27 2010-05-06 武田薬品工業株式会社 二環性化合物
EP2351743A1 (en) * 2008-10-27 2011-08-03 Takeda Pharmaceutical Company Limited Bicyclic compound
WO2011136385A1 (en) 2010-04-27 2011-11-03 Takeda Pharmaceutical Company Limited Bicyclic compound derivatives and their use as acc inhibitors.

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
"Comprehensive Organic Transformations", 1989, VCH. PUBLISHERS INC.
"Jikken Kagaku Kouza", vol. 20, THE CHEMICAL SOCIETY OF JAPAN, pages: 276 - 278
"ORGANIC FUNCTIONAL GROUP PREPARATIONS", 1989, ACADEMIC PRESS, INC.
"Part I: Diagnosis and Classification of Diabetes Mellitus", 1999, WORLD HEALTH ORGANIZATION, article "World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications"
"Protective Groups in Organic Synthesis", 1980, JOHN WILEY AND SONS
ANALYTICAL SCIENCES, vol. 10, no. 1, 1994, pages 17 - 23
IYAKUHIN NO KAIHATSU: "Design of Molecules", vol. 7, 1990, HIROKAWA SHOTEN, article "Development of Pharmaceuticals", pages: 163 - 198
JEFFREY W. CORBETT ET AL: "Inhibitors of Mammalian Acetyl-CoA Carboxylase", RECENT PATENTS ON CARDIOVASCULAR DRUG DISCOVERY, vol. 2, no. 3, 1 November 2007 (2007-11-01), pages 162 - 180, XP055002486, ISSN: 1574-8901, DOI: 10.2174/157489007782418928 *
JOURNAL OF THE CHEMICAL SOCIETY, 1937, pages 1530 - 1534
JOURNAL OF THE MEDICINAL CHEMISTRY, 2000, pages 3434 - 3442
JOURNAL OF THE MEDICINAL CHEMISTRY, 2006, pages 5282 - 5290
TETRAHEDRON LETTERS, 1980, pages 769 - 770
TETRAHEDRON LETTERS, 2001, pages 8345 - 8349
THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 285, 2001, pages 2486 - 2497

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703758B2 (en) 2010-04-27 2014-04-22 Takeda Pharmaceutical Company Limited Bicyclic compound
US9133129B2 (en) 2011-10-24 2015-09-15 Takeda Pharmaceutical Company Limited Bicyclic compound
US10815214B2 (en) 2012-12-07 2020-10-27 Merck Sharp & Dohme Corp. Regioselective N-2 arylation of indazoles
US10435386B2 (en) 2012-12-07 2019-10-08 Merck Sharp & Dohme Corp. Regioselective N-2 arylation of indazoles
EP2928473A4 (en) * 2012-12-07 2016-06-08 Merck Sharp & Dohme REGIOSELECTIVE N-2-ARYLATION OF INDAZOLES
US9580407B2 (en) 2012-12-07 2017-02-28 Merck Sharp & Dohme Corp. Regioselective N-2 arylation of indazoles
CN105008348A (zh) * 2013-03-14 2015-10-28 赛隆制药股份公司 吡唑基苯并[d]咪唑衍生物
CN105008348B (zh) * 2013-03-14 2018-07-10 赛隆制药股份公司 吡唑基苯并[d]咪唑衍生物
WO2015036892A1 (en) 2013-09-12 2015-03-19 Pfizer Inc. Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris
WO2015097713A1 (en) 2013-11-14 2015-07-02 Cadila Healthcare Limited Novel heterocyclic compounds
US10246470B2 (en) 2013-11-14 2019-04-02 Cadila Healthcare Limited Heterocyclic compounds
US10011609B2 (en) 2013-11-14 2018-07-03 Cadila Healthcare Limited Heterocyclic compounds
CN104193731A (zh) * 2014-08-27 2014-12-10 广东东阳光药业有限公司 新型脲取代联苯类化合物及其组合物及用途
US11059836B2 (en) 2014-08-29 2021-07-13 Chdi Foundation, Inc. Probes for imaging huntingtin protein
US12258355B2 (en) 2014-08-29 2025-03-25 Chdi Foundation, Inc. Probes for imaging huntingtin protein
CN104447725B (zh) * 2014-10-22 2018-02-02 浙江大学 一种手性含亚胺吡啶噁唑啉的化合物及其制备方法
US10022387B2 (en) 2015-02-09 2018-07-17 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
US10596184B2 (en) 2015-02-09 2020-03-24 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
US10233156B2 (en) 2015-03-30 2019-03-19 Shionogi & Co., Ltd. 9-membered fused ring derivative
RU2702637C2 (ru) * 2015-03-30 2019-10-09 Сионоги Энд Ко., Лтд. Производные бензимидазола или имидазопиридина, полезные для лечения или профилактики болезней, ассоциированных с асс2
AU2021201573B2 (en) * 2015-09-29 2022-02-17 Oncotherapy Science, Inc. Bicyclic compound and use thereof for inhibiting suv39h2
US10508109B2 (en) 2015-09-29 2019-12-17 Oncotherapy Science, Inc. Bicyclic compound and use thereof for inhibiting SUV39H2
EP3355699A4 (en) * 2015-09-29 2019-06-19 OncoTherapy Science, Inc. BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITION OF SUV39H2
CN105601626A (zh) * 2015-11-04 2016-05-25 浙江大学 一种含2-取代噁唑啉衍生物的制备方法
US10065963B2 (en) 2015-11-06 2018-09-04 Incyte Corporation Heterocyclic compounds as PI3K-γ inhibitors
US10472368B2 (en) 2015-11-06 2019-11-12 Incyte Corporation Heterocyclic compounds as PI3K-γ inhibitors
US11773102B2 (en) 2015-11-06 2023-10-03 Incyte Corporation Heterocyclic compounds as PI3K-γ inhibitors
US11091491B2 (en) 2015-11-06 2021-08-17 Incyte Corporation Heterocyclic compounds as PI3K-y inhibitors
US11952367B2 (en) 2016-01-05 2024-04-09 Incyte Corporation Pyridine and pyridimine compounds as PI3K-gamma inhibitors
US11352340B2 (en) 2016-01-05 2022-06-07 Incyte Corporation Pyridine and pyridimine compounds as PI3K-gamma inhibitors
US10138248B2 (en) 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
US10479795B2 (en) 2016-06-24 2019-11-19 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors
US12030885B2 (en) 2016-06-24 2024-07-09 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors
US10975088B2 (en) 2016-06-24 2021-04-13 Incyte Corporation Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors
US11629137B2 (en) 2017-04-24 2023-04-18 Tesaro, Inc. Methods of manufacturing of niraparib
US11161834B2 (en) 2017-04-24 2021-11-02 Tesaro, Inc. Methods of manufacturing of niraparib
US11225486B2 (en) 2017-10-18 2022-01-18 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
US11926630B2 (en) 2017-10-18 2024-03-12 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
US10738057B2 (en) 2017-10-18 2020-08-11 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
US11186580B2 (en) 2018-09-05 2021-11-30 Incyte Corporation Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor
US12173006B2 (en) 2018-09-05 2024-12-24 Incyte Corporation Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor
WO2023090411A1 (ja) 2021-11-19 2023-05-25 塩野義製薬株式会社 心疾患または骨格筋の疾患の治療用医薬
WO2023217989A1 (en) 2022-05-12 2023-11-16 Syngenta Crop Protection Ag Alkoxy heteroaryl- carboxamide or thioamide compounds
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds
WO2024126650A1 (en) 2022-12-15 2024-06-20 Syngenta Crop Protection Ag Novel bicyclic-carboxamide compounds useful as pesticides

Also Published As

Publication number Publication date
ECSP13012719A (es) 2013-12-31
UY33756A (es) 2012-06-29
CN103347872B (zh) 2014-12-24
EP2649062B1 (en) 2015-04-08
EP2649062A1 (en) 2013-10-16
MX2013006113A (es) 2013-11-01
US8729102B2 (en) 2014-05-20
ES2536319T3 (es) 2015-05-22
PE20140161A1 (es) 2014-02-19
WO2012074126A9 (en) 2013-06-06
AR084032A1 (es) 2013-04-17
SG190925A1 (en) 2013-07-31
PH12013501099A1 (en) 2013-07-08
CL2013001520A1 (es) 2013-10-18
TW201242951A (en) 2012-11-01
CN103347872A (zh) 2013-10-09
US20120142714A1 (en) 2012-06-07
AU2011337565A1 (en) 2013-07-11
CR20130281A (es) 2013-10-07
CO6751239A2 (es) 2013-09-16
EA201390794A1 (ru) 2013-11-29
CA2819400A1 (en) 2012-06-07
BR112013013417A2 (pt) 2019-09-24
MA34713B1 (fr) 2013-12-03
JP2013545718A (ja) 2013-12-26
AU2011337565A2 (en) 2013-07-11
KR20140001965A (ko) 2014-01-07
DOP2013000118A (es) 2013-09-30
JP5824517B2 (ja) 2015-11-25

Similar Documents

Publication Publication Date Title
EP2649062B1 (en) Bicyclic compounds as inhibitors of acetyl-coa carboxylase (acc)
US9238639B2 (en) Aromatic ring compound
US9133129B2 (en) Bicyclic compound
CN103025716B (zh) 二环化合物衍生物及其作为acc抑制剂的用途
EP2210876A1 (en) Heterocyclic compound
WO2012108478A1 (ja) 単環化合物
US9073864B2 (en) Aromatic ring compound
TW201350491A (zh) 雙環化合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11802168

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2819400

Country of ref document: CA

Ref document number: 2013524677

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2013001520

Country of ref document: CL

Ref document number: 226628

Country of ref document: IL

Ref document number: 12013501099

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 0183313

Country of ref document: KE

WWE Wipo information: entry into national phase

Ref document number: 001328-2013

Country of ref document: PE

Ref document number: MX/A/2013/006113

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: CR2013-000281

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 20137016850

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13144

Country of ref document: GE

Ref document number: A201308168

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 201390794

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: DZP2013000414

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 2011337565

Country of ref document: AU

Date of ref document: 20111129

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013013417

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013013417

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130529